LOBEF (Lobe Sciences) Total Liabilities: $2.35 Mil (As of Feb. 2026)


What is Lobe Sciences Total Liabilities?

Lobe Sciences LOBEF +12.45% Total Liabilities is $2.35 Mil as of Feb. 2026. The stock has 2 warning signs investors should review.

Lobe Sciences's Total Liabilities for the quarter that ended in Feb. 2026 was $2.35 Mil.

Lobe Sciences's quarterly Total Liabilities increased from Aug. 2025 ($1.96 Mil) to Nov. 2025 ($2.37 Mil) but then declined from Nov. 2025 ($2.37 Mil) to Feb. 2026 ($2.35 Mil).

Lobe Sciences's annual Total Liabilities increased from Aug. 2023 ($1.83 Mil) to Aug. 2024 ($2.47 Mil) but then declined from Aug. 2024 ($2.47 Mil) to Aug. 2025 ($1.96 Mil).

Lobe Sciences Total Liabilities Historical Data

* Premium members only.

The historical data trend for Lobe Sciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lobe Sciences Total Liabilities Chart

Lobe Sciences Annual Data
Trend Dec16 Dec17 Dec18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.64 1.01 1.83 2.47 1.96

Lobe Sciences Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.65 3.33 1.96 2.37 2.35

Lobe Sciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Lobe Sciences's Total Liabilities for the fiscal year that ended in Aug. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.758+(0.198+-5.5511151231258E-17
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.96

Total Liabilities=Total Assets (A: Aug. 2025 )-Total Equity (A: Aug. 2025 )
=5.5-3.544
=1.96

Lobe Sciences's Total Liabilities for the quarter that ended in Feb. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.12+(0.232+-2.4980018054066E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.35

Total Liabilities=Total Assets (Q: Feb. 2026 )-Total Equity (Q: Feb. 2026 )
=3.703-1.351
=2.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $2.35 Mil mean?
Lobe Sciences (LOBEF) has a Total Liabilities of $2.35 Mil as of Feb. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Lobe Sciences and its competitors.
Is Lobe Sciences' Total Liabilities too high?
Lobe Sciences' current Total Liabilities is $2.35 Mil.
How does Lobe Sciences' Total Liabilities compare to VRTX and REGN?
Lobe Sciences' Total Liabilities of $2.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Lobe Sciences and its competitors. Lobe Sciences's current Total Liabilities is $2.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lobe Sciences stock overvalued right now?
Lobe Sciences (LOBEF) has a current Total Liabilities of $2.35 Mil. The current Total Liabilities is $2.35 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Lobe Sciences (LOBEF), the current Total Liabilities is $2.35 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lobe Sciences Business Description

Other Exchanges LOBE:GermanyLOBE:Canada
Address 1771 Robson Street, No. 1614, Vancouver, BC, CAN, V6G 3B7
Lobe Sciences Ltd is a biopharmaceutical company focused on using lipid technology that develop therapies for orphan and rare diseases. It commercializes Altemia MF, a medical food intended to address nutritional deficiencies associated with sickle cell disease. Through its subsidiaries, the company also holds a majority interest in the development of Conjugated Psilocin for potential use in neurological and psychiatric indications. The company operates in one reportable segment, being the biopharmaceutical development of new medicines.